Discovery & Early Development Services
KCAS Bio is poised to perform bioanalytical drug discovery including assessment of a compound’s physiochemical properties, metabolite screening, bioavailability, toxicity and pharmacokinetics. KCAS Bio brings the full power of LBA and LC-MS/MS to your Drug Discovery and early stage research projects.
Rapid, rigorous drug discovery services
KCAS Bio organizes teams around early-stage rapid method development and analysis, as well as regulated preclinical and clinical phases, with support offered through NDA submission. We help with study design and perform the TK assessment once the bioanalytical data are available.
Our people
Tell us how we can help with your project
We've earned our reputation for delivering reliable, error-free data. We understand the importance of speed, flexibility, and consistency and only make promises we can keep.
Related services
Resources & insights
Podcasts
In episode 87 of The Weekly Bioanalysis podcast, John Perkins and Dawn Dufield preview the upcoming WRIB conference, where KCAS Bio and Sciex will both have strong representation through scientific presentations, panels, and business development efforts. Special guest, Rahul Baghla of Sciex, discusses the company’s collaboration with KCAS Bio and introduces their…
Blogs
Ligand binding assays (LBAs) have been our core activity for decades. LBAs are commonly used to measure interactions between two proteins, a ligand and its receptor, a monoclonal antibody (mAb) and its target, or biologics and Anti-Drug Antibodies (ADA). Throughout the development of New…
Blogs
In an exciting development, KCAS, through its subsidiary FlowMetric, is expanding its flow services in Europe. With a history of providing cutting-edge flow services in the EU, KCAS is taking a significant step forward by transitioning services from its Milan, Italy site to…
Agile, responsive, and easy to work with
We prepare and adapt our services based on a deep understanding of your drug development ambitions and wider business objectives.